Since its establishment in 1992 the Colorado SPORE Tissue Bank and Biomarkers Core Laboratory (TBBC) has consistently aimed to 1. provide well characterized tissues and products derived from those tissues to SPORE investigators, 2. assess status of submitted specimens by histological, immunohistochemical and fluorescence in situ hybridization, 3. link specimens to clinical data including outcomes in rigid compliance with standards for maintenance of patient confidentiality and informed consent. The development of targeted treatments has engendered an urgent need to know the status of the targeted pathway, the most striking examples of which are tyrosine kinase receptor and arachidonic acid pathways. RNA, DMA and protein biomarker status can efficiently be analyzed using core equipment and standardized methods in a single core laboratory. The Core will accordingly perform standardized molecular tests including quantitative RT-PCR and mutational analysis on extracts of tissue specimens obtained in support of individual SPORE research projects. Data from this testing is centrally tracked and distributed to SPORE clinical and basic science investigators who may then incorporate these data into hypothesis generation and testing. The expanded role of the Core in biomarker testing has prompted a name change for the core to Tissue Bank and Biomarkers Core Laboratory. The Core provides specimens and testing results for invasive tumors and is the central biorepository for unique and actively accruing early detection and chemoprevention trials for both the Colorado SPORE and the national SPORE program, collecting data and specimens from high risk patients without carcinoma at the time of enrollment. The Core is a unique source of biological materials that are used to investigate molecular changes that accompany and may predict invasive tumor. Specific services provided by the Core include consenting and enrollment of patients into tissue collection trials, preparation of kits for efficient sample collection and storage, sample procurement including but not limited to retrieval of tissue from operating and bronchoscopy suites, barcoding, accessioning and proper storage of SPORE specimens, histological sectioning and diagnosis of SPORE tissue samples, immunohistochemistry, and fluorescence in situ hybridization (FISH). In addition, specimens are prepared for RT-PCR, mutational analysis and oligonucleotide microarray studies required in the SPORE projects. Finally, specimens and data, including images (see Bronchial Map Project) are tracked through the central SPORE computer system and are available to SPORE investigators for outcome and clinicoepidemiological correlations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-18W1
Application #
8719577
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
18
Fiscal Year
2013
Total Cost
$123,330
Indirect Cost
$43,315
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Symonds, Jennifer M; Ohm, Angela M; Tan, Aik-Choon et al. (2016) PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells. Oncotarget 7:17905-19
Dziadziuszko, Rafal; Le, Anh T; Wrona, Anna et al. (2016) An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol 11:1273-81
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Scarborough, Hannah A; Helfrich, Barbara A; Casas-Selves, Matias et al. (2016) AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin Cancer Res :
Poczobutt, Joanna M; Nguyen, Teresa T; Hanson, Dwight et al. (2016) Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. J Immunol 196:891-901
Li, Bob T; Ross, Dara S; Aisner, Dara L et al. (2016) HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol 11:414-9
Yoshida, Takeshi; Song, Lanxi; Bai, Yun et al. (2016) ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One 11:e0147344
Ariyawutyakorn, Witthawat; Saichaemchan, Siriwimon; Varella-Garcia, Marileila (2016) Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer 7:633-49
Bunn Jr, Paul A; Minna, John D; Augustyn, Alexander et al. (2016) Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 11:453-74
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322

Showing the most recent 10 out of 350 publications